skip to Main Content

Montreal’s La Presse covers life science research funding project among MI, CQDM, OCE and OBI

This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program.

The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research.

Continue Reading

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

Raphael Hofstein's guest blog post for MEDI websiteAt the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor.

The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot project, which has produced Encycle Therapeutics.

Continue Reading

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces.

A French version of this release is available via CQDM’s website.

This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to increase innovation, productivity, investment and job creation.

Continue Reading

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery

BOSTON, June 18, 2012 – Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.

Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.

Continue Reading

The Accelerator Gazette Interviews Dr. Hossein Rahnama About Student Entrepreneurship

Ryerson University, one of MaRS Innovation’s 16 member institutions, has created the Digital Media Zone (DMZ) to give student entrepreneurs and researchers — or anyone connected with a great idea connected to their campus — the space they need to grow their ideas.

Dr. Hossein Rahnama, the DMZ’s research director and a Ryerson University professor, was interviewed this week by The Accelerator Gazette about Ryerson’s approach to accelerating and incubating technologies.

Continue Reading

OtoSim Inc. Makes a Sound Pitch on BNN

OtoSim listens to the Verdict on BNN's The Pitch
Louis Hui (far left) listens to the panel’s comments on BNN’s The Pitch.

OtoSim Inc., a MaRS Innovation spin-off company, made its debut on Business News Network’s The Pitchon June 1, 2012.

Louis Hui, OtoSim’s business development manager, had 90 seconds to pitch OtoSim™ — an integrated educational system that dynamically and interactively teaches how to accurately diagnose ear diseases — to The Pitch’s panel of financiers and experts.

Continue Reading
Back To Top